Vancouver, British Columbia–(Newsfile Corp. – February 24, 2021) – NeonMind Biosciences Inc. (CSE: NEON) (FFE: 6UF) (“NeonMind“), announces that it has purchased an initial order of GMP grade psilocybin from Psygen Labs Inc. (“Psygen“) for its planned phase 2 human clinical trial expected to begin in Canada later this year. Psygen is a Calgary-based company specializing in the synthetic…


Previous articleBeckley Psytech appoints ex-pharma CEO as Chief Operating Officer
Next articleEntheon Biomedical Corp. Provides Update on Subsidiary, HaluGen Life Sciences